ProCE Banner Activity

CodeBreaK101: Phase Ib/II Study With Sotorasib + RMC-4630, an SHP2 Inhibitor, in Advanced NSCLC and Other Solid Tumors With KRAS p.G12C Mutation

Slideset Download
Conference Coverage
Sotorasib plus RMC-4630 appears well-tolerated with promising response rates for previously treated patients with advanced NSCLC and a KRAS p.G12C mutation.

Released: August 12, 2022

Expiration: August 11, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc